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Gram-positive infections have increased in recent years, particularly those that are of nosocomial origin, leading 
to a broad use of agents with activity against these pathogens. Concomitantly, antimicrobial resistance of these 
pathogens also became widespread. Among the most common Gram-positive resistant pathogens are: Streptococcus 
pneumoniae, resistant to penicillin and macrolides, methicillin-resistant Staphylococcus aweus (MRSA), glycopeptide- 
intermediately-resistant S. aureus (GISA), methicillin-resistant S. epidermidis, glycopeptide-resistant enterococci and 
vancomycin-resistant enterococci (VRE). The response of the pharmaceutical industry to this challenge was the 
development of new antibiotics active against these pathogens. Among these antibiotics, this review will focus on: 
linezolid, an oxazolidinone; GAR-936, a tetracycline derivative; daptomycin, a lipopeptide; and ortivancin (LY- 
333328), a glycopeptide related to vancomycin. Except for linezolid, which has been recently launched in many 
countries, all other agents referred to in this review are still at various developmental stages. It is hoped that in the 
near future most of these agents will be approved and thus the grim outlook of patients infected with resistant Gram- 
positive bacteria may improve. 
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Emerging bacterial resistance to many available anti- 
microbial agents has led to a recent surge of pharma- 
ceutical development, which has resulted in production 
of several new antibiotics. Whereas resistant Gram- 
negative bacteria were a major problem in previous 
years, the past decade has seen a crescendo of problems 
with Gram-positive bacteria, including multidrug- 
resistant staphylococci, penicillin-resistant Streptococcus 
pneumoniae, and vancomycin-resistant enterococci 
(VRE). Novel agents, almost all derivatives of old com- 
pounds, have recently been introduced into clinical 
practice. 
In this review we focus on leading anti-Gram- 
positive compounds. We discuss their mode of action, 
antimicrobial properties and the clinical experience 
available from data derived from the best-designed 
clinical trials. As a result of space limitations we will not 
review all new agents, such as: the new fluoroquinolones, 
ramoplanin, beta-lactams, and the quinupristin/dalfo- 
pristin, which is already on the market. The reader is 
advised to refer to specific reviews on each drug. 
LINEZOLID 
The oxazolidinones are a unique family of antimicrobial 
agents, first developed in the late 1970s for agricultural 
use.l The agents are effective against a wide range of 
Gram positive bacteria, anaerobes and Mycobacterium 
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tuberculosis. Linezolid was the first derivative with 
acceptable tolerability in man to advance to clinical 
trials, and is the first Federal Drug Administration 
approved oxazolidinone for the treatment of pneumonia 
and skin and soft tissue infections caused by susceptible 
organisms, and infections caused by VRE. It has not yet 
been approved for the treatment of penicillin-resistant 
Streptococcus pneumoniae.2 
Eperezolid is an additional oxazolidinone agent that 
is presently undergoing clinical trials. 
Mechanism of action 
Oxazolidinones exert their antibacterial activity via 
inhibition of the initiation phase of bacterial protein 
synthesis.3 The compounds bind to the 50s ribosome 
where chloramphenicol and lincomycin competitively 
inhibit their binding. However, unlike these drugs, the 
oxazolidinones have no effect on the peptidyl trans- 
ferase.4 Therefore, similar to chloramphenicol and linco- 
samides, the oxazolidinone are usually bacteriostatic,5,6 
however there is no cross-resistance between the oxazo- 
lidinones and chloramphenicol or the lincosamides. 
Antimicrobial activity 
Linezolid possesses activity against staphylococci, 
including Staphylococcus aureus, irrespective of its 
oxacillin susceptibility,7,8 and against the recently 
isolated glycopeptide-intermediately-resistant S. aureus 
(GISA).9,Lo Linezolid is active against glycopeptide- 
resistant coagulase-negative staphylococci.7 In addition, 
activity against other major multidrug-resistant Gram- 
positive pathogens, including VRE and penicillin- 
resistant Streptococcus pneumoniae has also been 
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demonstrated, independent of their resistance profile to 
other antibacterials.*J1J2 Linezolid is also active against 
anaerobic streptococci, Clostridia spp. and Gram- 
negative anaerobes. However, it has limited activity 
against Gram-negative bacteria. The Enterobacteriaceae 
and Pseudomonas spp. are usually not susceptible. 
Resistance 
Enterococci and staphylococci resistant to linezolid can 
be selected in vitro, with difficulty, in association with 
mutations in genes encoding the central loop domain V 
of 23s rRNA.13 Thus far, in the clinical setting, resistance 
to linezolid has predominantly been reported in 
enterococci, especially when subtherapeutic drug 
concentration was used, and for the treatment of non- 
removable foci of infection.l&l7 Recently, a clinical 
isolate of Staphylococcus aureus resistant to linezolid 
has also been described. Interestingly, this resistant 
isolate was recovered from a patient treated with 
linezolid for peritonitis caused by a different S. aureus 
strain that was sensitive to linezolid. Pulsed-field gel 
electrophoresis revealed that the two strains were 
unrelated.ls 
Thus, linezolid is active against a wide range of 
Gram-positive pathogens through a unique mode of 
antibacterial action, without a cross-resistance with 
other agents. Therefore, it has a potential role in the 
treatment of nosocomial infections with a low risk of 
emerging resistance. This review reports on three 
randomized, double-blind equivalence trials evaluating 
linezolid in the treatment of nosocomial pneumonia and 
skin and soft tissue infection (SSTI). 
Clinical trials 
Nosocomial pneumonia 
In a randomized, double-blind, multicentre study, 
linezolid (600 mg twice daily) was compared to vanco- 
mycin (1 g twice daily), both antibiotics were adminis- 
tered concomitantly with aztreonam for the treatment 
of nosocomial pneumonia. l9 A group of 396 patients 
were included in the intention-to-treat (ITT) analysis. 
Groups were well matched with regard to patient 
characteristics. Over 52% of patients were at least 
65 years old. In addition, more than 50% were on 
mechanical ventilation at study entry, and more than 
50% had multiple lobe involvement. Mean APACHE II 
scores were similar, and above 20 in approximately 33% 
of the patients. The clinical cure-rate was defined as 
resolution or improvement of baseline symptoms and 
radiographs with no requirement for additional 
antimicrobial therapy. Clinical cure rate was achieved in 
71 (66.4%) out of 107 and 62 (68.1%) out of 91 clinically 
evaluable patients in the linezolid and vancomycin 
groups, respectively (Table 1). Microbiological eradi- 
cation rates were 25 of 41(61%) versus 15 of 23 patients 
(65.2%) for Staphylococcus aurcus, 15 of 23 (65.2%) 
versus 7 of 9 (77.8%) for methicillin-resistant S. aureus 
isolates (MRSA), and 9 of 9 (100%) versus 9 of 9 
(100%) for Streptococcus pneumoniae in the linezolid 
versus vancomycin groups, respectively. Therapeutic 
failures were similar in the two treatment groups. No 
patient who had a microbiological failure developed a 
resistant organism to either linezolid or vancomycin. 
There were no deaths as a result of therapeutic failure 
in the linezolid group, and four deaths (8.2%) in the 
vancomycin group. 
Skin and soft tissue infection 
In a randomized, double blind study, linezolid (400 mg 
twice daily) was compared with clarithromycin (250 mg 
twice daily) as treatment for uncomplicated SSTL20 The 
ITT groups comprised 332 patients, divided equally 
between the two treatment arms. The most frequent 
SST1 types were cellulitis, skin abscesses and furuncles. 
Clinical cure rates were similar between the two 
treatment groups. Clinical cure rate was achieved in 113 
(91%) out of 124 and 114 (93%) out of 123 clinically 
evaluable patients in the linezolid and clarithromycin 
groups, respectively (Table 1). For microbiologically 
evaluable patients, the microbiological success was 
98% and 97%, respectively. The rate of eradication of 
Staphylococcus aureus was 97% (38 of 39) for the 
linezolid arm and 96% (51 of 53) for the clarithromycin 
treatment group (Pharmacia, unpublished data). 
The efficacy of linezolid in complicated SST1 has 
also been assessed in a randomized, double-blind, 
multicentre study. 21 Linezolid (600 mg twice daily) was 
compared to oxacillin (2 g every 6 h). The excellent bio- 
Table 1. Clinical and microbiological efficacy of linezolid versus comparator drugs 
Infection site 
Nosocomial pneumonia 
Uncomplicated SST1 
Complicated SST1 
Treated(n) Drug 
203 Linezolid 
193 Vancomycin 
166 Linezolid 
166 Clarithromycin 
400 Linezolid 
419 Oxa/Dicloxacillin 
Clinical Microbiological 
cure rate (%) success (%) 
66 68 
68 72 
91 98 
93 97 
89 88 
86 86 
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availability of linezolid meant that, upon improvement 
of the patient’s condition, it could be switched, in the 
same dosage, to oral treatment. Oxacillin was switched 
to dicloxacillin. Concomitant aztreonam was added 
when deemed necessary. The ITT groups comprised 400 
linezolid-treated and 419 penicillinase-resistant penicillin- 
treated patients. The most frequent types of SST1 were 
cellulitis, skin abscesses and erysipelas. Clinical cure 
rates were similar, achieved in 264 (88.6%) out of 298 
and 259 (85.8%) out of 302 clinically evaluable patients 
in the linezolid and penicillinase-resistant penicillin 
groups, respectively (Table 1). Microbiological eradi- 
cation in was 88.1% and 86.1%, respectively, in 
StuphyZoccocus aureus cases: 85 (91.4%) out of 93 in the 
linezolid group versus 87 (54.5%) of 103 in the oxacillin 
group. However, patients infected by oxacillin-resistant 
strains were removed from the study. In the 
Streptococcus pyogenes-infected patients eradication 
rates were 23 (79.3%) of 29 and 27 (84.4%) of 32, for 
linezolid and oxacillin, respectively. In the group B 
streptococci the rates were 7 (100%) out of 7 and 4 
(77.7%) of 6, respectively. 
The efficacy of linezolid in the treatment of MRSA 
was evaluated in a randomized, open-label comparison 
with vancomycin. 22 The predominant infections were 
SST1 and pneumonia and the response rate between the 
two groups was similar. 
Safety 
Oxazolidinones are monoamine oxidase inhibitors 
and linezolid is a mild inhibitor. Patients should be 
counselled to avoid adrenergic agents, including food or 
beverages with a high tyramine contentI However, thus 
far no related adverse events have been noted.19,21 
Linezolid is a relatively safe drug; the most common 
adverse events are headache, diarrhoea and nausea.16 If 
therapy exceeds the recommended course of 28 days, 
bone marrow suppressive effects may appear. These 
effects (anaemia, thrombocytopenia and leucopenia) 
disappear when the drug is discontinued. 
In conclusion, linezolid proved effective in the 
treatment of nosocomial pneumonia and SST1 in 
randomized controlled studies, and also in community- 
acquired pneumonia, in randomized, single-blind and 
open-label studies (data not shown), all caused by 
Gram-positive organisms. Until now, penicillinase- 
resistant penicillin was the drug of choice for treating 
community-acquired SSTI. However, in view of the 
recent increase in oxacillin resistance among community- 
originating Staphylococcus aureus (MRSA),23 this 
practice needs a re-evaluation. Linezolid, effective 
against both oxacillin-sensitive and oxacillin-resistant 
strains of S. aureus becomes therefore an attractive 
alternative for empiric therapy for these infections. 
However, excessive use of this unique drug, might 
foster the emergence of drug-resistant pathogens, as 
has already been reported. Even though linezolid is 
approved for the treatment of nosocomial pneumonia, 
community-acquired pneumonia and SSTI, it would be 
prudent to administer it only in selected conditions, such 
as in vancomycin-intolerant patients with life-threaten- 
ing MRSA infections. 
DAPTOMYCIN 
Daptomycin is the first in a new class of cyclic 
lipopeptide drugs derived from the fermentation of 
Streptomyces roseosporus. It was first discovered in the 
1980s and was shown to be effective in the treatment of 
SSTI. However, because of muscle toxicity, which 
appeared at higher doses as used in the treatment of 
endovascular infections and endocarditis, and because 
of clinical failures,24 clinical trials were suspended. The 
emergence of infections caused by resistant Gram- 
positive bacteria led in 1997 to renewed interest in 
daptomycin, with new data obtained in the laboratory 
and in animal and human studies. 
Mechanism of action 
Daptomycin is bactericidal against a wide range of 
Gram-positive bacteria. It appears not to enter the 
cytoplasm of either bacterial or mammalian cells, but 
rather, in the presence of calcium ions, to disrupt 
bacterial membrane function.25a26 Calcium ions modu- 
late the hydrophobicity of daptomycin, facilitating its 
interaction with the target bilayer.27 Thereafter the 
daptomycin molecule dissipates, in a dose-dependent 
manner, the membrane action potential, with parallel 
loss of viability.28 
Antimicrobial activity 
Daptomycin is active solely against Gram-positive 
bacteria. In recent surveys from the United States and 
Europe, including over 3,300 isolates, daptomycin was 
active against all Staphylococcus aureus and coagulase- 
negative staphylococci, independently of their oxacillin 
susceptibility. Daptomycin was also active against beta- 
haemolytic streptococci, viridans streptococci, as well as 
against Gram-positive rods such as Leuconostoc, which 
are characteristically resistant to glycopeptides.29-31 
The effect of calcium in the medium was especially 
evident when enterococcal susceptibility was evaluated. 
Daptomycin was active against most strains, including 
VRE. However, added calcium increased the activity 
of daptomycin two- to fourfold.30,32 Unlike most other 
antibiotics, which are only bacteriostatic against 
enterococci, daptomycin exhibits rapid, concentration- 
dependent bactericidal activity against these pathogens, 
as well as against other bacteria.32 
Resistance 
Resistance to daptomycin among clinical isolates is 
rare.3o As expected, exposure of organisms to incre- 
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mental concentrations of daptomycin resulted in MICs 
8-32 times higher than those of the original isolates. 
Moreover, this resistance became stable and persisted 
even after passages in antibiotic-free medium.33,34 
Clinical trials 
Daptomycin has proven effective in various animal 
models of Gram-positive infections.35-37 To balance 
between the activity of daptomycin, which is concen- 
tration dependent, and the cytoskeletal toxicity, which is 
dose and time interval dependent, a once daily regimen 
was selected.38 
Consequently several global randomized, prospec- 
tive, double-blind phase III trials investigating the 
efficacy of daptomycin in the treatment of complicated 
SST1 and community-acquired pneumonia were 
initiated. One of the SST1 studies has recently been 
completed. In this study, 562 patients with major 
abscesses, wound infections and infected skin ulcers 
requiring hospitalization and parenteral antimicrobial 
therapy were enrolled. Patients received either dapto- 
mycin (4 mg/kg once daily i.v.) or vancomycin (1 g twice 
daily) or a penicillinase-resistant penicillin (4-12 g/day 
divided into four daily doses). Clinical success rates were 
equivalent in the daptomycin and the comparator arms. 
Clinical success in the ITT populations was 81% among 
the two arms, and in those clinically evaluable with 
Gram-positive pathogen(s), it was 91%. Clinically 
successful patients receiving daptomycin required fewer 
days of intravenous therapy than patients receiving the 
comparator agents. In addition, the incidence of total 
adverse events, particularly the feared muscle toxicity, 
was similar in both arms of the tria1.39 
Two multicentre, international, randomized, prospec- 
tive, double-blind studies evaluating daptomycin 4 mg/kg 
once daily i.v., versus ceftriaxone once daily i.v. in the 
treatment of community-acquired pneumonia are 
currently in progress.39 
The antibacterial spectrum of daptomycin, and its 
rapid bactericidal activity make this drug an attractive 
agent to be tested in the treatment of infective endo- 
carditis. Review of initial phase II studies, performed 
before clinical trials with the drug were halted for 
several years, indicate that daptomycin (3 mg/kg twice 
daily) was as efficacious as the comparator drug in the 
treatment of infective endocarditis.40,41 In a rat model of 
experimental Staphylococcus aureus endocarditis, dapto- 
mycin administered at a dose equivalent to 6 mg/kg in 
humans, was more effective than vancomycin. Even at 
a dose equivalent to 4 mg/kg in humans, daptomycin 
trended towards greater efficacy than vancomycin.42 
Safety 
Early development of daptomycin was suspended as a 
result of mild, reversible skeletal muscle damage, which 
manifested as myalgia and muscle weakness associated 
with elevated serum creatinine phosphokinase.43 In 
phase I and phase II trials daptomycin proved safe, and 
no serious adverse events were considered to be drug 
related.39,43 
GAR-936 
Tetracyclines have been important broad spectrum 
antimicrobial agents for the last 40 years. In order to 
overcome resistance to these drugs, modification of their 
structures was undertaken. Glycylcyclines are obtained 
by modification of the 9-position of chlortertracycline, 
minocycline, or doxycycline. GAR-936 is a novel deriv- 
ative of minocycline, active against tetracycline-resistant 
organisms.44 
Mechanism of action 
The tetracyclines act by inhibiting protein translation by 
reversibly interacting with the bacterial 30s ribosomal 
subunit, blocking the binding of aminoacyl tRNA to the 
mRNA-ribosome complex. Thus, preventing incorpor- 
ation of amino acid residues into the elongating peptide 
chains. Resistance is most commonly mediated through 
either efflux pump in both Gram-positive and Gram- 
negative bacteria, or by ribosomal alterations (‘changed 
target’) that diminish binding of the antibiotic in Gram- 
positive bacteria. 45 GAR-936 does not exhibit cross- 
resistance with many other tetracyclines.46 The differ- 
ence in the activity of tetracycline and GAR-936 is 
probably caused by a difference in the mechanism 
of action or a different mechanism of resistance. 
Glycylcyclines bind to the 70s ribosomal targets with 
five times greater affinity compared with the tetra- 
cyclines. 47 Experiments studying the mechanism by 
which glycylcyclines overcome efflux-based tetracycline 
resistance indicate that these substances are not recog- 
nized as substrates by the efflux pump.48 
Unlike tetracyclines that are generally considered 
bacteriostatic, GAR-936 possesses bactericidal activity 
against Streptococcus pneumoniae and bacteriostatic 
activity against most other Gram-positive cocci.49 
Antimicrobial activity 
GAR-936 is generally less active than its parent 
compound against minocycline sensitive, oxacillin- 
susceptible and -resistant staphylococci, but it does show 
in vitro activity against minocycline-resistant strains of 
Staphylococcus aureus and CONS. However, mean MIC 
against these isolates is higher than the MIC against the 
susceptible strains.50,51 In addition, GAR-936 inhibited 
two strains of GISA that were also resistant to tetra- 
cycline and minocycline, at MIC of 1 and 2 ug/ml.50 
Recently, GAR-936 was also shown to be active against 
six GISA strains, with a MIC of 0.06-1.0 mg/L.52 
Macrolide and tetracycline resistance occurs mainly 
in penicillin non-susceptible strains of Streptococcus 
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pneumoniae. On evaluation of isolates of penicillin- 
susceptible and penicillin-resistant S. pneumoniae, 
GAR-936 had lower MICs than tetracycline, mino- 
cycline and doxycycline. Its activity was independent of 
their penicillin susceptibility.4g,51 
Enterococcus spp. were sensitive to GAR-936, 
irrespective of their tetracycline susceptibility. This effect 
was predominantly evident against VRE, which are 
usually resistant to tetracycline and its derivatives.50,51 
GAR-936 possesses activity against Listeria rnono- 
cytogenes, similar to its parent compound.50 In addition, 
it was highly active against Gram-positive rods, including 
Lactobacillus spp., Leuconostoc spp. and Pediococcus 
spp? 
The activity against aerobic Gram-negative rods is 
fair. Many enterobacteriaceae, including Escherichia coli 
were inhibited by GAR-936 (Proteus spp. excluded). 
However, other strains were resistant, with the potency 
of other antibiotics, including ciprofloxacin, ceftazidime 
and imipenem, being significantly better.51,53 In addition, 
GAR-936 retains its activity against some nonfermen- 
tative bacteria such as Stenotrophomonas malto- 
philia, although it is not active against Pseudomonas 
aeruginosa.51~54 
GAR-936 also proved effective against a wide 
variety of aerobic and anaerobic animal and human bite 
wound pathogens.55 
Most strains of Neisseria gonorrhoeae are suscep- 
tible to GAR-936, including penicillin- or tetracycline- 
resistant strains.46,56 In addition, GAR-936 is highly 
active against other sexually transmitted diseases patho- 
gens, including Chlamydia trachomatis,57 as well as 
against Mycoplasma spp. and Ureaplasma urealyticum.58 
Resistance 
The glycylcyclines manifest the broad range of 
antibacterial activity that tetracycline had some years 
ago. However, particularly regarding staphylococci, 
GAR-936 potency is already lower than that of its 
parent compounds.50 
The most frequently occurring tetracycline-resistance 
determinant in Gram-negative bacteria encodes the 
membrane residing antiporter protein TetA, which 
catalyses active tetracycline efflux. Recently, two 
veterinary Salmonella isolates that carry a novel 
tetA(A) variant were found to have reduced suscepti- 
bility to glycylcyclines, although GAR-936, was the least 
affected.59 
Clinical trials 
Gar-936 is currently in phase II clinical trials. 
LY-333328 (ORITAVANCIN) 
Vancomycin was introduced in 1956 because of its 
effectiveness against penicillin-resistant staphylococci. 
Approximately 30-years later, acquired glycopeptide 
resistance in Enterococcus spp. was reported, followed 
by clinical isolates of GISA in 1997.60 However, to 
overcome resistance, vancomycin derivatives that have 
hydrophobic substituents on the vancosamine nitrogen 
have been developed. LY-264826 is a naturally occurring 
glycopeptide with the same core structure as vanco- 
mycin but with differences in associated sugars present.‘jl 
Alkyl modification of the disaccharide amino led to 
several compounds, the most active of which is LY- 
333328.61 
Mechanism of action 
The antibacterial activity of the glycopeptides results 
from their ability to bind intermediates involved in 
the biosynthesis of the cell wall peptidoglycan. The 
glycopeptide antibiotic binds to the terminal D-alanyl- 
D-alanine residues of the peptidoglycan precursor 
[lipid-linked disaccharide (N-acetyl-glucosamine-N- 
acetyl-muramic acid)-pentapeptide (L-Ala-D-Glu-L- 
Lys-D-Ala-D-Ala)] and inhibits the transglycosylase 
reaction, thereby an intermediate product is accumu- 
lating and polymerization of the peptidoglycan is 
prevented. 6o Resistance of enterococci to vancomycin 
results from replacing the terminal D-Ala-D-Ala with 
D-Ala-D-Lactic acid, which significantly reduces its 
affinity to vancomycin, sufficient to confer resistance (in 
a VanA-type). The inhibitory activities of glycopeptides 
that contain a hydrophobic side-chain (e.g. teicoplanin) 
is enhanced further, by virtue of the side-chain anchor- 
ing the agent at the membrane-associated target site, 
facilitating an intramolecular interaction.62 In addition, 
dimerization of glycopeptide molecules can also 
enhance their affinity to the cell wa11.62 
LY-333328 and related compounds act at the same 
site in peptidoglycan synthesis as vancomycin in both 
vancomycin-sensitive and vancomycin-resistant entero- 
cocci.63 The property of the new glycopeptides that 
possibly contributes to their enhanced antibacterial 
activity, is their propensity to form dimers and anchor to 
the cell membrane in a manner similar to teicoplanin.63 
They do not, however, bind in a higher affinity to either 
D-Ala-D-Ala or D-Ala-D-Lactic acid termini.62 
Antimicrobial activity 
In vitro susceptibility assays of LY-333328 are method- 
dependent (broth microdilution vs. agar dilution, type of 
broth). In a study evaluating LY-333328 against VRE 
strains, the discrepancy in the MICs in different methods 
used was more than 16-fold, while with other agents the 
inter-assay variability was less pronounced.61,64 
In several global surveys, testing altogether over 
2000 strains, using the usual NCCLS recommended 
Mueller-Hinton broth microdilution assay, LY-333328 
proved effective against the major multi-drug-resistant 
Gram-positive bacteria.6567 
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LY-333328 was equally effective against oxacillin- 
susceptible and methicillin-resistant Staphybcoccus 
aureus (MRSA). However, its activity for most strains 
was either identical or less efficient than other glyco- 
peptides (vancomycin and teicoplanin).65,67 In addition, 
LY-333328 was highly active against methicillin- 
susceptible and methicillin-resistant CONS, including 
those resistant to teicoplanin.65-67 In a recent report 
evaluating the activity against three different GISA 
strains, LY-333328 was consistently, in a concentration- 
dependent manner, the most active glycopeptide, and 
showed synergism with gentamicin.68 
LY-333328 possesses good in vitro activity against 
enterococcal spp., including glycopeptide-resistant 
strains of the three major phenotypes (VanA,VanB, and 
VanC), with MICs significantly lower than the other 
glycopeptides.65-67,69 In another survey evaluating the 
antimicrobial susceptibility of 4,208 clinical isolates of 
enterococci, LY-333328 was highly effective, showing no 
cross-resistance with vancomycin.70 In addition, unlike 
the bacteriostatic effect of vancomycin and teicoplanin, 
LY-333328 manifested bactericidal activity against some 
of the strains tested.64,71 
Pneumococci, and other viridans streptococci, were 
highly susceptible to LY-333328, irrespective of their 
penicillin susceptibility, with current MICs lower than 
that of the other glycopeptides.65-67 LY-333328 was uni- 
formly bactericidal against Streptococcuspneumoniae.72 
Resistance 
In a series of experiments using laboratory-constructed 
enterococcal strains that acquired LY-333328 resistance. 
Resistance was mainly a result of mutations leading to 
production of precursors ending in D-Lac with complete 
elimination of precursors terminating in D-Ala.73 These 
observations indicate that emergence of LY-333328 
resistance should be anticipated. 
Clinical trials 
A phase II, open-label, controlled, multicentre study in 
patients with Staphylococcus aureus bacteraemia is on- 
going. An additional phase II, double-blind, multicentre 
study, for the treatment of patients with complicated 
SSTI, has finished enrolling patients. 
CONCLUSIONS 
Drug-resistant Gram-positive bacteria are a serious 
emerging problem in clinical practice. In particular, 
nosocomial strains resistant to all the antimicrobials are 
becoming increasingly common. Several new agents to 
combat these strains have been developed in recent 
years, linezolid (and quinupristin/dalfopristin) have 
already been approved by the United States Federal 
Drug Administration for several indications, whereas 
the other agents are still undergoing clinical trials. Thus 
far there have been only scant reports comparing head 
to head the above-reviewed new agents against the 
major pathogens, and in the majority no significant 
differences were found.74-76 One report indicated better 
activity of daptomycin versus linezolid against staphylo- 
cocci and enterococci.9 Therefore, other parameters, 
including the susceptibility profile of the isolated 
bacterium, should lead us in selecting the appropriate 
drug. At the present time it is impossible to forecast 
which agent would be clinically the most useful. In 
addition, the clinical safety profiles of these agents 
remain unknown. 
Many new antimicrobial agents are being evaluated 
yearly.77 However, only few enter clinical studies and 
less are eventually approved. It is somewhat discour- 
aging that among the more advanced agents targeted 
against Gram-positive pathogens, no true novel product 
exists, but rather they are derivatives of old molecules. 
Consequently the duration for which we should expect 
them to be clinically efficient before resistance emerges 
is limited. Therefore, in addition to dusting off old agents 
in the search for new drugs, we should be more judicious 
in using the current antibiotics in order not to induce 
resistance. It is hoped that with the unfolding of the 
genomic structure of many pathogens, newer targets 
allowing for new agent development will enrich the 
clinical arena with effective new agents. 
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